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ABSTRACT
Oral anticoagulants (OAs) are the recommended drugs to prevent cardiovascular 
events and recurrence in patients with atrial fibrillation (AF) and cardioembolic 
stroke. We conducted a literature search to review the current state of OAs 
pharmacogenomics, focusing on Genome Wide Association Studies (GWAs) in patients 
treated with vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs).
VKAs: Warfarin, acenocoumarol, fluindione and phenprocoumon have long been 
used, but their interindividual variability and narrow therapeutic/safety ratio makes 
their dosage difficult. GWAs have been useful in finding genetic variants associated 
with VKAs response. The main genes involved in VKAs pharmacogenetics are: VKORC1, 
CYP2C19 and CYP4F2. Variants in these genes have been included in pharmacogenetic 
algorithms to predict the VKAs dose individually in each patient depending on their 
genotype and clinical variables.
DOACs: Dabigatran, apixaban, rivaroxaban and edoxaban have been approved for 
patients with AF. They have stable pharmacokinetics and do not require routine blood 
checks, thus avoiding most of the drawbacks of VKAs. Except for a GWAs performed in 
patients treated with dabigatran, there is no Genome Wide pharmacogenomics data 
for DOACs. Pharmacogenomics could be useful to predict the better clinical response 
and avoid adverse events in patients treated with anticoagulants, identifying the most 
appropriate anticoagulant drug for each patient. Current pharmacogenomics data 
show that the polymorphisms affecting VKAs or DOACs are different, concluding that 
personalized medicine based on pharmacogenomics could be possible. However, more 
studies are required to implement personalized medicine in clinical practice with OA 
and based on pharmacogenetics of DOACs.
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Oral anticoagulants (OAs) are recommended drugs 
to reduce the risk of stroke and systemic embolism in 
patients with non-valvular atrial fibrillation (NVAF), and 
to treat and reduce the risk of deep venous thrombosis 
(DVT) and pulmonary embolism (PE) [1, 2].
OAs can be classified as vitamin K antagonists 
(VKAs) (warfarin, acenocoumarol, fluindione and 
phenprocoumon) [3] and direct oral anticoagulants 
(DOACs): dabigatran, apixaban, rivaroxaban and 
edoxaban [4, 5].
Pharmacogenetics of OAs
Genome Wide Association Studies (GWAs) have 
been very successful in finding genetic risk factors 
associated with complex diseases or with drug response 
(pharmacogenomics). This technique uses a general 
approach which allow a systematic agnostic research of 
common genetic factors across the whole genome [6, 7].
Furthermore, different GWAs analysis have 
been published describing variants associated with 
the interindividual and inter-ethnic variation of VKAs 
response [6–11] and, recently, also for dabigatran response 
[12]).
The aim of this review is to describe the genetic 
factors associated with the response of OAs drugs used in 
stroke and other cardiovascular diseases prevention and to 




An extensive literature search was performed, up to 
December 2017, on PubMed with the following key words: 
‘GWAs and warfarin’, ‘GWAs and acenocoumarol’, 
‘GWAs and fluindione’, ‘GWAs and phenprocoumon’, 
‘GWAs and dabigatran’, ‘GWAs and edoxaban’, ‘GWAs 
and rivaroxaban’ and ‘GWAs and apixaban’. Thirty-eight 
results were obtained for ‘GWAs and warfarin’, 6 of which 
were GWAs studies. For ‘GWAs and acenocoumarol’, 4 
results were obtained. Only 1 of them was a GWAs study 
performed on acenocoumarol. One result was obtained 
for ‘GWAs and phenprocoumon’ which corresponded to 
a GWAs analysis. Two results were found for ‘GWAs and 
dabigatran’; only one was a GWAs analysis in patients 
treated with dabigatran. For the other searches, no results 
were obtained (Figure 1, Supplementary Table 1).
In the case of drugs for which we did not find 
GWAS analyses, we searched in PubMed for other 
genetic studies, based on candidate genes, using the 
following terms: ‘Genetics and fluindione’, ‘Genetics and 
edoxaban’, ‘Genetics and rivaroxaban’ and ‘Genetics and 
apixaban’. We included three candidate gene studies for 
fluindione, one candidate gene study for edoxaban and 
one in vitro study for apixaban (Figure 1). We included all 
the original studies written in English including candidate 
gene analyses in more than 20 patients or in vitro studies 
analyzing the influence of one or more SNPs.
eQTLs analysis
We searched in GTEx portal 
(https://www.gtexportal.org/) the first and second most 
significant eQTLs genes for the SNPs from the published 
GWAs cited in this review (Supplementary Table 1), in 
two cases: 1-intragenic SNPs attributed to regulate other 
genes in the referenced paper; 2-intergenic SNPs (Table 
1). We indicated the tissue in which the most significant 
eQTL for a gene is expressed and also if it is expressed in 
relevant tissues for the disease.
VITAMIN K ANTAGONIST (VKA)
The first oral anticoagulant drug was discovered 
in 1941 through its identification as the cause of fatal 
bleeding in cattle [13]. These animals had eaten spoiled 
hay made from sweet clover which contained dicoumarol, 
a type of coumarin [14]. Since then, coumarins have long 
been used in the pharmaceutical industry to synthetize 
anticoagulant drugs due to their antagonistic effect on 
vitamin K [15].
VKAs are used worldwide. Warfarin is extensively 
used in North America, Scandinavia, the UK and Asian 
countries. Acenocoumarol and phenprocoumon are used 
in continental European countries [14, 16, 17]. Fluindione 
is widely used in France [18].
Warfarin and acenocoumarol are 
4-hydroxycoumarins, which are vitamin K epoxide 
reductase (VKOR) inhibitors [14]. They inhibit recycling 
of the inactive oxidized to the active reduced form of 
vitamin K, a cofactor involved in activation of coagulation 
factors II, VII, IX and X [19] (Figure 2A).
VKAs have demonstrated to be effective, preventing 
15 deaths and 15 non-fatal strokes per 1,000 patients with 
non-valvular AF. However, they caused 8 non-fatal major 
extracranial bleeds [20]. VKAs have a narrow therapeutic/
toxic ratio [7, 11, 16, 21, 22], and their daily dose varies 
between individuals and ethnic groups [23].
Normally, during the first days to weeks of 
treatment, the correct dose is not achieved as measured 
by the international normalized ratio (INR). INR values 
above 3 or 4 increase the bleeding risk, whereas INR 
values below 2 are associated with low efficacy of VKAs 
[24]. Patients may therefore be undertreated, increasing 
the risk of cardioembolism, or overtreated, leading to 
bleeding, as the therapeutic range is very small [6, 7, 21].
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WARFARIN
Warfarin is a racemic mixture comprised by S and 
R enantiomers. The S enantiomer has a half-life of 24-
33h, whereas R-warfarin has a half-life of 35-58h [14]. 
S-warfarin is the most potent enantiomer and is almost 
completely responsible for the anticoagulant effect. This 
enantiomer is metabolized almost exclusively by the 
hepatic cytochrome CYP2C9 enzyme [25, 26]. R-warfarin 
is metabolized by CYP1A1, CYP1A2 and CYP3A4 [27].
The daily dose of warfarin varies between 
individuals. Doses range from 2 to 10 mg per day [23]. 
Furthermore, different ethnicities often require different 
dose of warfarin: Asian populations often have a lower 
daily dose requirement (3 mg per day) compared to 
European and African populations (5 mg and 6.5 mg per 
day, respectively) [23].
Relevant non-genetic factors affecting warfarin dose 
variance include age, weight, body surface, gender, drug 
interactions, diseases and the quantity of vitamin K intake [28].
Pharmacogenetics
The main genetic factors affecting warfarin dose 
variance found and replicated in different retrospective 
Figure 1: Flow diagram in the selection of articles included in the review. 
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and prospective studies are SNPs in vitamin K epoxide 
reductase complex 1 (VKORC1) gene, in cytochrome 
P450 2C9 (CYP2C9) gene and in cytochrome P450 4F2 
(CYP4F2) gene [3, 6, 7, 16, 21, 23, 26, 28–34].
Several GWAs analyses were performed in different 
populations to analyze the association of genetics with 
warfarin dose variations [6–10] (Supplementary Table 
1). The largest GWAs analysis included 1,508 Japanese 
patients with the aim of finding associations with warfarin 
maintenance dose [8]. They found SNPs in VKORC1 
gene to be the most significantly associated with warfarin 
maintenance dose, followed by polymorphisms in 
CYP2C9 and CYP4F2 genes [8].
VKORC1
Most studies highlight VKORC1 as the most 
important gene in warfarin pharmacogenetics [6–9, 
35]. VKORC1 encodes the catalytic subunit of the 
vitamin K epoxide reductase complex, which reduces 
the inactive vitamin K to recycle it to the active form 
in the endoplasmic reticulum membrane [19, 36]. In 
the first reported systemic review and meta-analysis 
on the impact of polymorphisms in or near VKORC1 
gene on warfarin dosage requirement, which included 
19 studies and a total of 4,621 patients, the C allele in 
rs9934438, A allele in rs7294 and G allele in rs9923231 
were associated with an increase in the daily warfarin 
dose requirement [28]. The heterozygous rs7294 CT and 
rs9923231 GA carriers required a 50% higher dose than 
the homozygous rs9934438 TT and rs9923231 AA. The 
homozygous rs9934438 CC and rs9923231 GG carriers 
required approximately double the dose of rs9934438 
TT and rs9923231 AA. The effect of rs7294 SNP on the 
warfarin dose requirement was less clear. However, rs7294 
A carriers required a dose approximately 30% higher than 
rs7294 GG carriers [28].
In three different GWAs studies, in Swedish, 
Japanese and African-American populations, the SNP 
rs9923231 upstream VKORC1 gene was also found 
to be significantly associated with the mean warfarin 
dose (Supplementary Table 1) [7–9]. The Swedish 
GWAs also found this SNP to be associated with over-
anticoagulation (INR > 4) during the first 5 weeks of 
treatment (Supplementary Table 1) [7]. rs9923231 was 
linked to rs10871454 (associated with daily maintenance 
dose in the Caucasian GWAs analyses) [6, 35]. In the 
GWAs in African-American population [9], rs9934438 
in the VKORC1 gene was also associated with a stable 
maintenance warfarin dose (Supplementary Table 
1), considering the maintenance dose as a stable 
dose of three or more clinical visits. SNPs in linkage 
disequilibrium (LD) with rs9923231 on chromosome 16 
were also significantly associated with stable warfarin 
dose [9].
Figure 2: Mechanism of action of the different OAs and polymorphic genes associated with OAs response. (A) Mechanism 
of action of VKAs. (B) Mechanism of action of DOAC. *Genes with polymorphisms associated with OAs variation in GWAs.
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Table 1: Most significant eQTLs for significant intergenic SNPs in AOs GWAs
SNP from GWAS 
(Supplementary 
Table 1)
Gene Near gene 















CYP2C19 6.9e-31 Esophagus - Mucosa
MTND4P19 3.5e-14 Skin
rs2104162 CYP2C9
CYP2C19 1.1e-10 Esophagus- Mucosa





C10orf129 1.2e-12 Adipose - Subcutaneous
CYP2C8 0.000077 Breast - Mammary Tissue
rs17126068 DDHD1
RP11-547D23.1 1.4e-9 Testis

















CYP2C19 1.1e-17 Esophagus - Mucosa
C10orf129 4.1e-10 Nerve - Tibiala
rs2104543 CYP2C18
CYP2C19 1.1e-15 Esophagus - Mucosa
C10orf129 3.8e-10 Nerve - Tibiala
rs12772169 CYP2C18
CYP2C19 2.1e-17 Esophagus - Mucosa






The SNP rs749671, downstream the VKORC1 
gene reached statistical significance in a GWAs study 
in a Brazilian population (Supplementary Table 1) [10]. 
The G allele of this SNP was strongly associated with 
a high warfarin dose requirement [10]. Other SNPs 
significantly associated with warfarin dose in the VKORC1 
region in this GWAs were rs749670 and rs14235 [10] 
(Supplementary Table 1).
We have searched the most significant eQTLs of 
the intragenic and intergenic SNPs attributed to regulate 
VKORC1 in the referenced paper. We have found that 
all these SNPs have eQTLs in VKORC1 expressed in 
whole blood, among other tissues (Table 1). These SNPs 
described to regulate VKORC1 have also eQTLs in KAT8, 
expressed in arteries (Table 1).
CYP2C9
The CYP2C9 gene encodes a member of the 
superfamily of the cytochrome P450 enzymes important 
in drug metabolism and lipids synthesis. CYP2C9 enzyme 
is relevant in the metabolism of almost all the S-warfarin 
in liver [26, 37]. The most described variants functionally 
associated with warfarin dosage are CYP2C9*2 
(rs1799853, R144C) and CYP2C9*3 (rs1057910, 
I359L), which are associated with lower warfarin dose 
requirements [26]. In a systemic review and meta-analysis 
including almost 8,000 genotyped individuals, it was 
reported that the heterozygous genotypes *1*2, *1*3, *2*3 
required 19,6%, 33,7% and 56,7%, respectively, lower 
doses compared to the wild type (WT) genotype *1*1. The 
homozygous genotypes *2*2 and *3*3 required 36% and 
78,1% lower doses compared to *1*1 genotype to achieve 
a stable INR [26]. These genotypes were more influential 
in individuals without interactions with other drugs [26]. 
CYP2C9 variants have an impact on different aspects in 
warfarin pharmacokinetics. Patients with CYP2C9*2 and 
CYP2C9*3 variants require a lower maintenance dose, 
more time to reach a stabilized dose (mean of 95 days) 
and have a higher risk of major bleeding compared to 
patients without these variants. Moreover, these variants 
are associated with the ratio of above-range INRs [23, 33].
Different GWAs have found other significant 
variants in CYP2C9 associated with mean warfarin dose. A 
GWAs study in a Swedish population confirmed previous 
results [38] about the significant association between the 
SNP rs4917639 in CYP2C9 and the mean warfarin dose 
given to a patient (Supplementary Table 1). This SNP was 
in almost complete LD with the composite of CYP2C9*2 
and CYP2C9*3 variants associated with lower warfarin 
dose requirements [7].
Another GWAs study in Japanese population 
identified the SNP rs10509680 in the CYP2C9 gene 
significantly associated with maintenance dosage of 
warfarin. The GG genotype of this polymorphism was 
associated with higher therapeutic dose requirement [8].
Finally, in a GWAs study performed in Brazil, 
rs4918798 and rs9332238 (the G allele) in or near CYP2C9 
were also associated with high warfarin dose. Rs9332238 
and rs4918798, the latter to a lesser degree, were in 
almost complete LD with CYP2C9*2 and CYP2C9*3 [10] 
(Supplementary Table 1).
CYP4F2
CYP4F2 is another member of the cytochrome 
P450 enzymes superfamily. This enzyme is a vitamin K1 
oxidase important in vitamin K metabolism [19, 30, 39].
In two GWAs, the variant rs2108622 CYP4F2*3 
(1297G>A) in the CYP4F2 gene was associated with 
warfarin dose [7, 8] (Supplementary Table 1). This variant 
was associated with a higher warfarin dose requirement. 
This mutation affects the metabolizing function of 
CYP4F2 over vitamin K [30]. The cytochrome encoded 
by the gene CYP4F2 inhibits vitamin E by hydroxylation 
of its tocopherol phytyl side chain. This side chain is 
SNP from GWAS 
(Supplementary 
Table 1)
Gene Near gene 














Enumeration of the most significant eQTLs for SNPs associated with AOs response located in 1) intragenic regions 
attributed to regulate other genes in the referenced paper; 2-intergenic regions. Column one: SNP ID (from Supplementary 
Table 1); Column two: gene, for intragenic SNPs; Column three: near gene described in the original GWAs to be the 
effector gene; Column four: most significant eQTLs from GTEx project. P-value indicated for the most significant eQTL 
in the gene; Column five: p-values for the most significant eQTL for each gene; Column six: tissues where the most 
significant eQTLs are expressed.
a Significant eQTL also in arteries (p<10-5); b Significant eQTL also in whole blood (p<10-5).
eQTL= expression quantitative trait loci; GTEx project= Genotype-Tissue Expression project.
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similar to the side chain of vitamins from the vitamin 
K group. Thus, it is possible that this cytochrome also 
inhibits vitamin K, and thereby the activation of vitamin K 
dependent coagulation factors is reduced when the enzyme 
works normally [11, 40]. Patients with the CYP4F2*3 
allele had higher levels of vitamin K1 in the liver and 
needed an increase of 1–2.5 mg/day in the warfarin dose 
to achieve proper anticoagulant effect [30].
In relation with ethnic origin, it has been observed 
that 50% of African-Americans have one of the above 
described variants in CYP2C9, VKORC1 or CYP4F2, 
whereas this percentage increases up to 90% in 
Asians, Caucasians, Hispanics and Ashkenazi Jewish 
populations [30].
Another GWAs has recently identified two SNPs 
in NEDD4 and 2kb downstream DDHD (rs2288344 
and rs17126068, respectively) associated with warfarin 
dose. In this GWAs, two SNPs in ASPH (rs4379440 and 
rs17791091) were associated with time in therapeutic 
range [35] (Supplementary Table 1).
Implications of warfarin pharmacogenetics
As a consequence of the studies published in 
relation to the pharmacogenomics of warfarin, in August 
2007 the US Food and Drug Administration (FDA) 
updated the warfarin labelling to incorporate information 
on the genotyping of VKORC1 and CYP2C9 to better 
adjust the warfarin dose [7, 28]. However, in April 
2009, the Centers for Medicare and Medicaid Services 
(CMS) decided not to routinely pay for the genotyping 
because they considered there had not been enough 
evidence supporting the improvement of this genetic test 
in patient’s health. CMS decided to pay only the genetic 
test in patients enrolled in specifically designed post-
marketing clinical trials [41].
Another consequence of the different pharmacogenetic 
studies on warfarin was the creation of the International 
Warfarin Pharmacogenetics Consortium (IWPC) to combine 
the efforts of warfarin pharmacogenetics researchers. 
The IWPC included 22 research groups from 11 different 
countries with total data from more than 5,700 patients 
treated with warfarin [42].
The described variants in VKORC1 and CYP2C9 
and the non-genetic factors explain roughly 50% of the 
interindividual variance in warfarin dose requirement [30]. 
Thus, around 50% of the warfarin dose variance remains 
unexplained. Specifically, VKORC1 polymorphisms 
explain about 27% (ranging from 15% to 34%) of the 
variance in the stabilized warfarin dose, whereas the 
CYP2C9 polymorphisms contribute on average 12% 
(ranging from 4 to 20%) [29]. Furthermore, polymorphism 
in CYP4F2 (rs2108622) explains roughly 1.5% of warfarin 
dose variation [7].
Many algorithms have been designed including 
genetic and non-genetic factors to attempt to predict the 
appropriate initial or daily stable warfarin dose [16, 21, 
42–52].
Gage et al. designed a pharmacogenetic algorithm 
(PA) using stepwise regression in a multicenter study 
cohort. They used an additive genetic model, numbering 
the variant alleles at each locus from 0 to 2. The variables 
included were weighted according to their ratio of 
variance on the therapeutic warfarin dose. They tested 
the effect of several clinical and demographic variables 
and only retained variables that were significantly 
independent predictors of warfarin dose in the derivation 
cohort (N=1,015 patients). The formula was analyzed 
prospectively in 292 patients from the validation cohort 
[21]. The pharmacogenetic equation included the 
1639G>A VKORC1 polymorphism, CYP2C9 *2 and *3 
polymorphisms and physiological and clinical factors 
such as body surface area, age, target INR, amiodarone 
use, smoker status, African-American race and current 
thrombosis. This equation explained 53-54% of the 
warfarin dose variance. When the genetic factors were not 
included, the equation explained 17-21% of the warfarin 
dose variability and had higher prediction error [21]. In 
patients from the validation cohort, the warfarin dose was 
prescribed prospectively using the PA or an almost equal 
preliminary version of this algorithm. These patients took 
a first warfarin dose without accounting for CYP2C9*2 
and CYP2C9*3 alleles. During the 30-day follow-up, 2 
patients had a major hemorrhage or PE and 3 patients had 
symptomatic DVT. They demonstrated the feasibility and 
safety of the pharmacogenetics algorithm [21].
Recently, two prospective randomized trials were 
designed to compare patients with initial warfarin dose 
based on PA or clinical decision [45, 46]. In one of the 
studies, patients were randomized receiving warfarin 
by a validated algorithm (96 patients) [53] or CYP2C9 
genotype-adjusted algorithm (95 patients) [46]. They 
found that the inclusion of CYP2C9 polymorphisms 
information decreased minor bleedings and improved the 
INR control, reaching the first therapeutic INR and stable 
anticoagulation earlier [46]. In the other study, 200 patients 
were randomized (101 patients treated using PA and 99 
using standard clinical decision). They received warfarin 
and had at least 1 follow-up INR to prospectively validate 
the pharmacogenetics-guided dosing formula (determined 
by a regression equation) [45]. The primary endpoint was 
the percentage of out-of-range INRs. They did not find 
significant differences in the ratio of patients with out-
of-range INR. However, PA more accurately predicted 
the individual dose when the patients were divided into 
subsets: patients without allele variants (WT), patients 
with a single allele variant and patients with multiple allele 
variants. The PA was better than the standard decision for 
predicting the higher average warfarin dose in WT and 
the lower dose in patients with multiple allele variants. 
Despite not being statistically significant, total adverse 
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events were lower in patients with dose predicted based 
on PA than on standard decision [45].
Pharmacogenetic refinement algorithms have 
been developed to validate whether genotype can 
refine maintenance dose of warfarin after some days of 
therapy. One study derived clinical and pharmacogenetics 
refinement algorithms using INR values on day 4 or 5, 
clinical factors quantified using stepwise selection and 
genotype [16]. Variables which achieved statistical 
significance in the multivariable linear regression model 
and thereby were maintained were: INR, A allele of 
the 1639G>A polymorphism in VKORC1, CYP2C9*2 
and CYP2C9*3 alleles, prior warfarin dose, age, BSA, 
stroke, diabetes, race, target INR and use of amiodarone 
or fluvastatin. The clinical refinement algorithm was 
similar to the pharmacogenetics algorithm but without 
the inclusion of genotype and race [16]. In the derivation 
cohort (N=969), the pharmacogenetics algorithm explained 
63% of variation (R2), whereas the clinical algorithm 
had an R2 of 48%. The PA was tested in 204 patients of 
the internal validation cohort who had INR available on 
day 4th of therapy. The R2 was 58%, whereas the R2 for 
clinical algorithm was 43% [16]. Algorithms were also 
tested in another validation cohort of 105 patients with 
INR values measured on day 5th. In this case, the R2 for 
the PA was 60%, whereas the R2 for the clinical algorithm 
was 44% [16]. Similar results were obtained when final 
algorithms were validated in an external validation cohort 
(N=517 patients with INR measurements on day 4th of 
therapy; N=438 patients with INR measurements on day 
5th of therapy). The authors concluded that PAs were 
more accurate than clinical algorithms for predicting the 
maintenance dose of warfarin [16].
PAs developed to predict the initial therapeutic dose 
of warfarin have shortcomings [21, 45, 46]. They do not 
indicate how to dose warfarin when the INR response to 
the therapy is known. Furthermore, in some occasions the 
time to obtain the genotyping results is too longer. Some 
experts have argued that when the genotyping of VKORC1 
and CYP2C9 will be available in practice they may be 
not relevant or cost-effective. The initiation algorithms 
have been developed in small populations, with some 
exception. Thus, the predictive value of these algorithms 
in large populations could be different [16]. Hence, a 
large controlled, multicentre and randomized trial seems 
necessary to quantify the effect of pharmacogenetics 
algorithms in INR control and in the occurrence of adverse 
events [21]. In addition, for PA to be used in clinical 
practice, it is necessary to include the pharmacogenetics 
technology and knowledge in the clinical infrastructure 
[34].
The International Warfarin Dose-Refinement 
(Warfarin DR) Collaboration was created to develop and 
validate a pharmacogenetics refinement algorithm in an 
international cohort of patients and determine whether the 
genotyping predicts the therapeutic dose, also when the 
INR value is available in the 4th or 5th day after the therapy 
initiation [16].
ACENOCOUMAROL
Acenocoumarol is a racemic mixture comprised 
by S and R enantiomers. S-acenocoumarol is the most 
potent enantiomer and it is metabolized by the CYP2C9 
enzyme, while R-acenocoumarol is metabolized by 
CYP1A2, CYP3A4, CYP2C9 and CYP2C19. The half-
life of S-acenocoumarol is 1.8 hours and the half-life of 
R-acenocoumarol is 6.6 hours [14]. The slower elimination 
of the R-enantiomer makes R-acenocoumarol responsible 
for the anticoagulant effect of this drug. R-acenocoumarol 
is the clinically most important enantiomer due to the short 
half-life of S-acenocoumarol [27].
Administration of acenocoumarol is also limited 
by the narrow therapeutic/toxic profile of this drug 
and the interindividual and interethnic dose variation. 
Environmental and genetics factors influence in 
acenocoumarol dose variation [54].
Pharmacogenetics
Variations in VKORC1, CYP2C9 and CYP4F2 are 
associated with changes on stabilized acenocoumarol 
dosage. VKORC1 and CYP2C9 genetic variants also 
correlate with the maintenance dose, the first INR 
after the initial standard dose, the time until the stable 
dose is achieved, the time until the correct therapeutic 
rank is achieved and the ratio of bleeding events of 
acenocoumarol [11].
Only one GWAs study has been performed on 
acenocoumarol pharmacogenetics. A large population-
based cohort of 1,451 Caucasian patients from the 
Rotterdam study and 287 individuals from the extended 
Rotterdam cohort in the replication were analyzed [11].
Near VKORC1 gene, the SNP rs10871454 in the 
Syntaxin-4 (STX4) gene was significantly associated 
with acenocoumarol dose variance in this GWAs and 
subsequently, replicated [11] (Supplementary Table 1). 
The authors suggested this polymorphism might decrease 
the hepatic expression of VKORC1 mRNA, decreasing 
the amount of the drug target [11]. Furthermore, this 
SNP was in complete LD with the rs9934438 SNP on 
the VKORC1 gene that is one of the polymorphisms 
associated with the dose variation in warfarin treated 
patients [11]. However, other roles are plausible to 
explain the association of the SNP in STX4 and the 
acenocoumarol dose variance. The protein encoded by 
STX4 is a SNARE molecule and SNAREs are involved 
in endothelial and other cells, such as platelets, secretion. 
However, its role in platelet exocytosis varies depending 
on secretary granules types, but appears to be essential 
for lysosomal release in platelets [55, 56]. Endothelial 
exocytosis is relevant in thrombosis, hemostasis and 
inflammation [57, 58].
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Regarding CYP2C9 gene, in this GWAs, the SNP 
rs4086116 was associated with interindividual variation 
on stabilized acenocoumarol dosage.
In the same study, the polymorphism rs2108622 in 
CYP4F2 was also associated with the acenocoumarol dose 
when the significant SNPs of VKORC1 and CYP2C9 were 
included in the analysis as covariates [11] (Supplementary 
Table 1). It has been postulated that the T allele of the 
rs2108622 variant decreased the enzyme activity, 
preventing vitamin K inactivation. Consequently, patients 
with one CYP4F2 allele variant need an increment of the 
dose of about 1mg/week per allele [40].
Polymorphisms within and flanking CYP2C18 and 
CYP2C19 gene were also associated with acenocoumarol 
maintenance dose and replicated in the replication stage [11].
The combination of the CYP2C9*3 genotype and the 
polymorphisms in 1639G>A or 1173C>T in the VKORC1 
gene explained around 50% of the interindividual 
variability on the anticoagulation effect of acenocoumarol 
[54]. In addition, the combination of variants in CYP2C9 
and VKORC1 was strongly associated with severe over-
anticoagulation [27]. The addition of the polymorphism 
rs2108622 (in CYP4F2) increased the r2 adjusted of the 
clinical and genetic (CYP2C9 and VKORC1) model for 
acenocoumarol dosage variation by 1.3%, while the 
addition of the polymorphism in CYP2C18 (rs1998591) 
increased the r2 adjusted by 1.2% [11].
Implications of acenocoumarol pharmacogenetics
Different acenocoumarol pharmacogenetic-guided 
dosing algorithms have been derived in different cohorts 
from different populations [17, 59–67]. An observational 
retrospective study analyzed 8 different acenocoumarol 
pharmacogenetic algorithms in a cohort of 189 patients 
[65]. The algorithm which achieved similar doses to 
the real stable doses was the EU-PACT algorithm [17]. 
However, considering the patients with over- or under-
estimation of the dose and patients correctly classified 
(deviation from the actual stable dose of ≤20%), the 
algorithm which classified most patients correctly was the 
Borobia algorithm [59]. This algorithm correctly classified 
40.7% of the 189 patients included [65]. However, an 
algorithm correctly classifying this percentage of patients 
remains far from being used in clinical practice.
PHENPROCOUMON
Phenprocoumon is another coumarin derivate 
from the VKA family which is also found as a racemic 
mixture. The S-phenprocoumon is the most potent 
enantiomer. The half-life of phenprocoumon is 110-130h 
for the S-enantiomer and 110-125h for the R-enantiomer 
[14]. Given the long half-life of phenprocoumon, over-
anticoagulated patients under this treatment have higher 
risk of major bleeding [27].
Phenprocoumon is metabolized by CYP3A4 enzyme, 
which is a non-polymorphic cytochrome [14]. The main role 
of CYP3A4 in the metabolism of phenprocoumon makes 
it safer than acenocoumarol and warfarin. 60% of oral 
phenprocoumon is metabolized, whereas 40% is excreted 
unchanged. Thus, phenprocoumon could be a better option 
for those patients that metabolise coumarin poorly [27].
Despite having a narrow therapeutic/toxic profile, 
patients treated with phenprocoumon achieve more stable 
INR measurements and require less monitoring [27].
Pharmacogenetics
It has been suggested than phenprocoumon 
metabolism is less influenced by the CYP2C9 genotype, 
with VKORC1 having greater relevance. It has been 
shown that patients with a CYP2C9 variant, and without 
VKORC1 variant alleles, required a 30% lower dose than 
WT patients. Patients with CYP2C9 and VKORC1 allele 
variants have an increased risk of over-anticoagulation. 
CYP2C9 genotype is also associated with delayed 
phenprocoumon stabilization [27].
A gene candidate study was performed with 
VKORC1, CYP2C9 and CYP4F2 genes. The authors 
found that an allele variant in VKORC1 decreased the 
maintenance dose of phenprocoumon by 4.8 mg/week. An 
allele variant in CYP2C9 also decreased the dose by 2.2 
mg/week and an allele variant in CYP4F2 increased the 
dose by 1.5 mg/week. They generated a clinical-genetic 
model including age, sex, BMI, target INR, VKORC1, 
CYP2C9 and CYP4F2 genotypes, explaining the 46% of 
the maintenance dose [68].
There is a GWAs study with 202 patients treated 
with phenprocoumon. The authors found 32 SNPs in 
chromosome 16 (within or flanking VKORC1 gene) 
significantly associated with phenprocoumon dose. The 
stronger associations were for the SNPs rs10871454 and 
rs11150604 (Supplementary Table 1). Both SNPs were in 
complete LD and were associated with a decrease in the 
dose. Both SNPs were found replicated in the validation 
cohort (n=42). Four additional SNPs nominally associated 
with phenprocoumon dose in chromosome 9 were found. 
However, they were not replicated [68] (Supplementary 
Table 1).
FLUINDIONE
Fluindione is an inandione derivate widely used in 
France (about the 80% of OA prescription in this country) 
[69]. Unlike coumarin derivates, fluindione is not found as 
a racemic mixture [70].
Knowledge of the pharmacokinetics of fluindione 
is scarce. An intermediate half-life has been described 
for fluindione, similar to the half-life of the more potent 
enantiomer of warfarin [18]. One study described a 
fluindione half-life of 31h [71], while another found a 
median half-life of 69h [70]. Fluindione is less often 
displaced by other drugs in their receptors and it has 
higher affinity to albumin than warfarin [70]. The role of 
CYP2C9 is unknown in the fluindione metabolism [72].
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The efficacy and, thereby, the dose of fluindione, 
varies among patients depending on environmental 
and genetic factors. The individual fluindione dose 
varies between 5 and 40 mg per day [18, 73, 74]. The 
interindividual variability of this drug is associated with 
the same adverse events as with the other VKAs, mainly 
thromboembolic events and bleedings.
Pharmacogenetics
No GWAs study was performed in fluindione 
treated patients. Only some candidate gene analyses 
have evaluated the genes that could be implicated in 
the interindividual variability of fluindione. However, it 
would be necessary to perform GWAs in fluindione to find 
reliable associations.
In a study including 465 patients with a venous 
thromboembolic event, several polymorphisms in 
VKORC1, CYP2C9, CYP4F2 and EPHX1 genes were 
analyzed [72]. The C1173T polymorphism in VKORC1 
gene was associated with different outcomes: the risk 
of a first INR measure ≥ 2, the mean time to achieve 
an INR measure in therapeutic range (2-3), the time 
to have a first INR > 4 (over-anticoagulation). The 
target dose of fluindione was also associated with the 
C1173T polymorphism. Patients with a T allele in 
this polymorphism were more sensitive to fluindione, 
achieving the first INR in therapeutic range earlier, with 
an increased risk of over-anticoagulation (achieving a INR 
value > 4 before) and with a decrease of more than a half 
the dose of patients with CC genotype [72]. However, 
these results were not replicated in a validation cohort.
Another study analyzed different variables which 
could be influencing the fluindione clearance in 24 
healthy white patients. The CYP2C9*2 and *3 genotype, 
VKORC1 1173 C>T genotype, CYP1A2 phenotype and 
body weight were found to be predictors of the fluindione 
pharmacodynamics and pharmacokinetics [18].
To predict the fluindione dose in an elderly 
population, one study analyzed 13 polymorphisms 
in 7 genes (VKORC1, CYP4F2, EPHX1, CYP2C9, 
CYP2C19, CYP3A5 and ABCB1) potentially involved 
in the pharmacological effect or in the metabolism/
transport of fluindione in 156 patients. The variables 
body weight, amiodarone intake, VKORC1, CYP4F2 
and ABCB1 genotypes were included in a prediction 
model. This model explained 31,5% of the dose 
variability and the accuracy in the prediction of the 
dose within 5mg per day of fluindione was 89,7%. 
The model was validated in 74 patients, obtaining the 
correct dosing within 5mg per day in 83,3% of the 
patients. Patients with a variant allele 2kb upstream 
VKORC1 (rs9923231) and patients with a variant allele 
in ABCB1 2677 G>T/A required lower doses than 
WT patients. Interestingly, comparing with coumarin 
derivates, CYP2C9 was not associated with fluindione 
maintenance dose, suggesting the possible use of 
fluindione in patients hypersensitive to coumarins [74].
There are some differences among the different 
VKAs. They have different pharmacokinetics, such as 
different half-life [14]. In pharmacogenetics, there are 
also some differences in the variants associated with 
dose variation of the different VKAs. Only in the case of 
acenocoumarol, polymorphisms flanking CYP2C18 were 
identified associated with the acenocoumarol variation 
dose [27]. Furthermore, CYP2C9*2 has different effect in 
patients treated with acenocoumarol or warfarin. While 
CYP2C9*2 allele decreases the warfarin maintenance dose, 
this variant does not affect the acenocoumarol dose [27]. In 
addition, the CYP2C9 genotype seems to be less relevant 
for the phenprocoumon and fluindione dose variation than 
for the other VKAs [27, 74]. Moreover, CYP1A2 appears 
to have a more important role for fluindione than for the 
other VKAs [18].
DIRECT ORAL ANTICOAGULANTS 
(DOACS)
Nowadays, 4 DOACs have been developed to try to 
overcome the drawbacks of VKAs. Rivaroxaban, apixaban 
and edoxaban are direct oral factor Xa inhibitors, whereas 
dabigatran is a direct oral thrombin inhibitor [75] (Figure 
2B).
DOACs are taken in fixed doses and the coagulation 
status does not need to be monitored periodically [12]. 
Furthermore, it has been observed that DOACs have fewer 
interactions with other drugs such as digoxin, aspirin or 
nonsteroidal anti-inflammatory drugs or with food [76].
All DOACs have been shown to be safe and 
effective alternatives to warfarin [77].
Different reviews and meta-analysis have analyzed 
data from real-world studies, registries and databases in 
patients with non-valvular AF. In general, they concluded 
that rivaroxaban is associated with lower rates of ischemic 
stroke or systemic embolism compared to warfarin [77]. 
The initiation of rivaroxaban is associated with higher 
risk of major bleeding compared to apixaban [78] but 
with lower risk of intracranial bleeding compared to 
warfarin [79].
Apixaban and dabigatran are associated with 
lower ratio of major bleeding compared to warfarin [77] 
and both, apixaban and dabigatran, have similar major 
bleeding rates [78]. They are also associated with lower 
ratio of intracranial bleeding compared to warfarin [79, 
80]. Both apixaban and dabigatran are associated with 
lower death rates compared to warfarin [77].
In general, DOACs are similar to warfarin 
preventing ischemic stroke [77, 80], however with a lower 
risk of bleeding [77].
DABIGATRAN
Dabigatran is approved by the FDA and European 
Medicines Agency (EMA) and indicated for reducing 
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the risk of stroke and systemic embolism in patients with 
NVAF [1, 2].
Dabigatran is a reversible direct thrombin inhibitor 
effectively completely converted by the liver esterase 
CES1 from the oral prodrug dabigatran etexilate to the 
active drug [12, 81, 82]. Dabigatran etexilate is a substrate 
of the P-glycoprotein intestinal efflux transporter (encoded 
by ABCB1 gene), an efflux pump for xenobiotics. 
Dabigatran is excreted predominantly by renal pathway 
(80%) [83]. Maximum plasma concentrations of 
dabigatran are achieved at 1 to 3 hours after the dose 
intake [12].
Recently, idarucizumab, a reversal agent for 
dabigatran action was approved by the FDA and the EMA 
to treat dabigatran patients with any bleeding or requiring 
emergency surgery [84].
Several real-world studies with dabigatran have 
been performed to determine its effectiveness in clinical 
practice. A meta-analysis of 20 observational real-
world studies comparing patients with NVAF treated 
with dabigatran and with VKA found the incidence 
of ischemic stroke, major bleeding and mortality was 
lower for dabigatran than for VKA. However, the risk of 
gastrointestinal (GI) bleeding was higher for the patients 
treated with dabigatran (Supplementary Table 2) [85].
Another meta-analysis including 7 observational 
real-world studies found similar results (Supplementary 
Table 2). However, they observed a similar rate of stroke 
between patients treated with dabigatran and patients 
treated with warfarin. Furthermore, the higher ratio for 
GI bleeding was potentiated in the elderly subgroup 
(≥75 years). They included two studies which analyzed 
the GI risk in patients using dabigatran 110 mg. One of 
these studies found a similar risk compared with warfarin 
in patients < 75 years and a higher risk for dabigatran in 
patients ≥75 years. The other study found lower risk of GI 
for dabigatran 110 mg compared to warfarin in patients 
< 75 years. In general, the bleeding outcomes from this 
meta-analysis were in concordance with the ones in the 
RE-LY phase III clinical trial [80].
Other datasets included patients with NVAF treated 
with dabigatran. All of them observed lower risk for major 
bleeding, intracranial bleeding and death for patients 
treated with dabigatran compared to patients treated with 
warfarin (Supplementary Table 2). These associations 
were stronger for dabigatran 150 mg. Risk of major GI 
bleeding was similar or higher for patients with dabigatran 
treatment compared to warfarin. Risk of ischemic stroke 
was lower or similar between both drugs (Supplementary 
Table 2) [86–90]. The Danish registry compared the 
bleeding rates of VKA naïve patients and patients in 
treatment with VKA switched to dabigatran. They 
observed that warfarin starters had the highest bleeding 
rates. Dabigatran 110 mg switchers from VKA had higher 
rates of bleeding compared to patients continuing warfarin 
treatment [88–90].
Dabigatran 75 mg was approved in the USA for 
patients with renal impairment. In an observational study, 
it was observed that the ratio for stroke, mortality and 
bleeding was similar in patients treated with dabigatran 
75 mg and in patients treated with warfarin. However, the 
ratio for intracranial bleeding was lower for dabigatran 
patients. However, most of patients included in this 
study treated with dabigatran 75 mg did not have renal 
impairment, so the prescription of this drug was off-label 
[91, 92].
Dabigatran, like the other DOACs, is taken in a 
fixed dose. However, there are interindividual differences 
between patients in blood concentration (estimation of 
30% variation for systemic exposure) [12].
The unique GWAs with patients treated with 
DOACs was developed to identify variants associated 
with interindividual variability in dabigatran etexilate 
blood concentration. 1,694 patients of white European 
ancestry from the RE-LY study treated with dabigatran 
were analyzed. The polymorphism rs2244613 in 
the esterase gene CES1 was associated with trough 
concentrations (each minor allele was associated with 
15% decrease in trough concentrations) and with lower 
risk of any bleeding. The polymorphisms rs4148738 
in the ABCB1 gene and rs8192935 in CES1 gene were 
associated with peak concentrations but not with clinical 
outcome [12]. However, the results were not analyzed 
in a replication cohort. Importantly, both genes (ABCB1 
and CES1) encode for proteins related to dabigatran 
pharmacokinetics, which means that variants in genes 
related to dabigatran absorption and metabolism explain 
part of the variations in dabigatran concentrations between 
individuals [12].
Another study in 92 patients with AF has recently 
evaluated the effect of the three polymorphisms found 
in the dabigatran GWAs analysis (rs2244613 and 
rs8192935 in CES1 gene and rs4148738 in ABCB1 
gene) to analyze the influence of these polymorphisms 
on the interindividual variation in dabigatran 
concentration. They found significant association of the 
SNP rs8192935 in CES1 gene with dabigatran trough 
concentration [93].
It is relevant that VKAs and dabigatran have 
different metabolic pathways. These differences are 
also observed in pharmacogenetics studies: different 
polymorphisms in different genes are associated with 
metabolic variance for each drug. Consequently, future 
drug decision could be performed in those patients based 
on their genetic background.
RIVAROXABAN
Rivaroxaban is a direct oral inhibitor of the 
Xa factor approved by EMA and FDA, indicated for 
prevention of stroke and systemic embolism in patients 
with non-valvular AF [1, 2].
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Rivaroxaban does not require coagulation 
monitoring. The pharmacokinetics of rivaroxaban is 
dose-proportional and it has high oral bioavailability and 
maximum plasma concentrations at 3-4 hours after drug 
intake, which can be affected by the co-administration of 
food [83]. Rivaroxaban is not recommended in patients 
with moderate or severe hepatic impairment, as the 
clearance of rivaroxaban is decreased [83]. Rivaroxaban 
exhibits little interindividual variability based on age, 
gender and body weight [94].
This drug is a substrate of the P glycoprotein and is 
metabolized through CYP3A4/5 and CYP2J2 (two-thirds 
of rivaroxaban) and CYP independent mechanisms [82, 
83, 94].
Approximately 1/3 of unchanged rivaroxaban is 
eliminated by the kidneys. The other 2/3 of rivaroxaban is 
metabolized by the liver [95].
There are different studies, registries and databases 
describing the use of rivaroxaban in real-world for patients 
with AF [96–103].
In a meta-analysis of 9 studies [96], the results 
obtained (Supplementary Table 2) were in concordance 
with the results from the ROCKET-AF clinical trial, 
confirming the benefit-risk profile of rivaroxaban [97, 99].
The Xantus study, a prospective, observational, phase 
IV analysis, observed that patients with higher CHADS2 
and CHA2DS2-VASc (a scale for the risk of stroke and 
systemic embolism) had higher rates of stroke and systemic 
embolism, major bleeding and death [99, 100].
Different registries and datasets have found results 
which were similar to the ROCKET-AF phase III clinical 
trial observations [98, 99, 101] (Supplementary Table 2). 
In general, the ratio of intracranial bleeding and ischemic 
stroke were lower for rivaroxaban compared to VKAs [99, 
102, 103] (Supplementary Table 2).
There are no GWAs studies performed in patients 
treated with rivaroxaban. It is possible that polymorphisms 
in genes involved in the metabolism of the drug could 
be associated with rivaroxaban blood levels, similar 
to the results found with warfarin, acenocoumarol 
and dabigatran. Taking into consideration the proteins 
associated with the absorption (P-glycoprotein) 
and metabolism (CYP enzymes) of rivaroxaban, 
polymorphisms in ABCB1 gene or CYP genes could be 
associated with rivaroxaban concentration in blood.
APIXABAN
Apixaban, like rivaroxaban, is a direct oral inhibitor 
of the Xa factor. Apixaban is indicated by the EMA and 
FDA for reducing the risk of stroke and systemic embolism 
in patients with non-valvular AF. It is used in patients with 
risk factors (previous stroke, high blood pressure, diabetes, 
heart failure or being ≥75 years old) [1, 2].
The bioavailability of apixaban is around 50% and it 
reaches the maximum concentration 1-3 hours after intake. 
Its half-life is between 8 and 15 hours. Roughly 25% of 
the drug is excreted by the kidneys [104]. Apixaban is also 
a substrate for the P-glycoprotein transporter and mainly 
for CYP3A4/5 [83] but also CYP 1A2, 2C8, 2C9, 2C19, 
2J2 [94].
A genetic study on the effect of rs4148738 
polymorphism in ABCB1 gene in apixaban concentrations 
(the same polymorphism of the dabigatran GWAs) showed 
an association with apixaban peak concentrations [105]. 
However, it would be necessary to perform GWAs to really 
assess which genes are important for the interindividual 
variability.
Currently, there are no GWAs studies in patients 
treated with apixaban. Taking into account the proteins 
associated with the metabolism of rivaroxaban, it is 
possible that polymorphisms in the ABCB1 gene or CYP 
genes which metabolize apixaban (CYP3A4/5, CYP 
1A2, 2C8, 2C9, 2C19 and 2J2) could be associated with 
rivaroxaban blood levels, similar to the results found with 
warfarin, acenocoumarol or dabigatran.
EDOXABAN
Edoxaban, such as rivaroxaban and apixaban, is a 
direct oral inhibitor of factor Xa indicated by the FDA 
for reducing the risk of stroke and systemic embolism in 
patients with non-valvular AF [2]. EMA has also approved 
edoxaban to prevent stroke and systemic embolism in 
patients with non-valvular AF, but in this case only in 
patients who have one or more risk factors (previous 
stroke, high blood pressure, diabetes, heart failure or being 
≥ 75 years old) [1].
Edoxaban achieves maximum plasmatic 
concentrations within 1 to 2 hours after being taken. It 
has predictable pharmacokinetic profile and 62% oral 
bioavailability. Edoxaban, as the other DOACs, is also 
a substrate of the P-glycoprotein. It is metabolized 
by hydrolysis through a carboxylesterase (CES) and 
oxidized by the CYP enzyme CYP3A4 [82]. Some 50% 
of edoxaban is excreted by kidneys [106].
A meta-analysis of 24 real-world studies included 
patients with AF to analyzed patients treated with a daily 
dose of edoxaban 30 mg or 60 mg versus placebo (no 
treatment), aspirin and aspirin plus clopidogrel. They 
observed how treatment with edoxaban 30 mg decreased 
the risk for all stroke, ischemic stroke and mortality. 
Patients treated with edoxaban 30 mg versus patients 
treated with aspirin plus clopidogrel had a lower risk of 
intracranial hemorrhage. Edoxaban 60 mg reduced the 
risk of any stroke and systemic embolism versus placebo, 
aspirin and aspirin plus clopidogrel. Thus, both edoxaban 
doses had a positive net clinical benefit compared to 
antiplatelet treatment or no treatment in the real world 
[107].
Another study with patients from the Danish 
nationwide cohort tested the hypothesis that edoxaban 
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had a net clinical benefit (NCB), which is the balance 
between systemic embolism and intracerebral bleeding, 
superior to warfarin. Comparing without treatment, 
warfarin had a NCB of 0.26 prevented events per 100 
patients-years, edoxaban 60 mg had a NCB of 0.71 per 
100 patients-years and edoxaban 30 mg had a NCB of 0.71 
per 100 patients-years. At all CHADS2 and CHA2DS2-
VASc score, both edoxaban doses had higher NCB than 
warfarin. At CHA2DS2-VASc scores 0 and 1, warfarin had 
no positive NCB compared to no treatment. In patients 
with CHADS2 and CHA2DS2-VASc score ≥ 2, edoxaban 
60 mg had a better NCB than edoxaban 30 mg and 
warfarin. At CHA2DS2-VASc scores 0 and 1, edoxaban 30 
mg had superior NCB than edoxaban 60 mg. In patients 
with HAS-BLED score ≤ 2 (a scale for the risk of major 
bleeding), both warfarin doses had higher NCB compared 
to warfarin independently of the CHADS2 and CHA2DS2-
VASc scores. In patients with a HAS-BLED score ≥ 3, 
both edoxaban doses had positive NCB compared to 
warfarin, in patients with CHADS2 and CHA2DS2-VASc 
score ≥ 2 [108].
One in vitro study was performed with the purpose 
of determining if two polymorphisms in factor Xa 
(Ala152Thr and Gly192Arg) were affecting the edoxaban 
activity. The authors concluded that these mutations do 
not account for the interindividual variability of edoxaban 
[109].
There are no GWAs studies performed in patients 
treated with edoxaban. Studies analyzing the role 
of ABCB1 gene, or genes involved in the edoxaban 
metabolism (CYP3A4 or CES such as dabigatran), and the 
response to edoxaban could be interesting.
CONCLUSIONS
Variants in CYP2C9, VKORC1 and CYP4F2 are 
associated with VKAs dose variation between individuals. 
However, these variants together with non-genetic factors 
explain about 50% of the interindividual dose variation 
[7, 30]. Further analyses with more patients are necessary 
to find other genetic variations associated with dose 
variations or with vascular events and dosing treatment. 
However, other mechanisms could explain the remaining 
percentage of variation, such as rare mutations, epigenetics 
mechanisms and environmental factors. To find rare 
mutations, it would be necessary to perform exome 
sequencing or whole genome sequencing as was done 
for statin drugs [7]. For epigenetics, some mechanisms 
such as DNA methylation could be implicated in OAs 
dose variation. Some studies have found how DNA 
methylation modifications could be influencing the effects 
of antiplatelet drugs [110, 111].
Diverse pharmacogenetics algorithms have been 
developed, including polymorphisms in CYP2C9 and 
VKORC1 together with clinical variables to predict the 
initial dose of warfarin. The different PAs improved 
the accuracy and efficiency of warfarin dose initiation. 
However, the results are controversial in the reduction of 
out-of-range INRs. Some studies observed that genotyping 
variants in CYP2C9 improves INR control [46], whereas 
other studies did not find the usefulness of these algorithms 
to control INR [21, 45]. Although the percentage of out-
of-range INRs is not statistically significant among 
patients treated according to PA or clinical/standard 
decision in these studies, PA more accurately predicted 
the individual dose depending on the subset of patients 
(WT, with one single allele variant, with multiple allele 
variants). The percentage of each of these subsets of 
patients could differ between studies and cause the 
mentioned differences among studies. Moreover, VKORC1 
have not been genotyped in all studies and could modify 
the results and conclusions. Probably larger number of 
patients are necessary to achieve higher statistically power 
to observe differences among PA and clinical algorithms. 
Moreover, the genetic variants identified to date explain 
only a proportion of the drug response, thus more genetic 
variants can contribute to increasing the percentage of 
drug variability and may be included in pharmacogenetics 
algorithms [34].
To improve the main shortcomings of VKA, mainly 
the frequent monitoring, DOACs have been approved 
for the prevention of stroke recurrence and systemic 
embolism in patients having suffered a previous stroke 
with non-valvular AF, to treat DVT or PE. DOACs have 
a better efficacy-safety profile compared to warfarin 
(Daiichi Sankyo Europe GmbH 2014). Patients treated 
with DOACs have a lower ratio of bleeding events 
(rivaroxaban, apixaban and edoxaban) and life-threatening 
bleeding (dabigatran). Furthermore, the use of DOACs 
reduces intracranial bleeding compared to warfarin. In 
patients with AF, the results from the different pivotal 
clinical trials suggest that DOACs improve the outcomes 
of these patients [15]. Altogether, the information on the 
four DOACs from the clinical trials shows that they are 
not inferior to warfarin in terms of efficacy, although they 
seem to reduce bleeding events, improving their safety. 
However, DOACs have greater acquisition costs. Thus, 
greater cost versus greater efficacy/safety profile and 
avoidance of monitoring have to be balanced [112]. A 
review of the use of DOACs in an elderly population with 
non-valvular AF demonstrated that they are beneficial and 
lead to a reduction of stroke risk in this population [76].
Due to the lack of GWAs with DOACs (only one) 
[12], it would be important to perform pharmacogenetic 
studies based on a GWAs approach. It is possible that 
some genes could be associated with the metabolism of all 
or almost all DOACs, such as ABCB1, which is involved 
in the transport of all DOACs, or CYP3A4, involved in 
the metabolism of all DOACs with the exception of 
dabigatran [82, 94]. Furthermore, it could be interesting 
to assess whether there are polymorphisms associated with 
the response to the different DOACs in terms of efficacy 
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(risk of stroke or systemic embolism) and safety (risk of 
bleeding).
Pharmacogenetics could be useful to identify the 
more appropriate anticoagulant for each specific patient, 
avoiding adverse events such as any bleeding or stroke 
recurrence. VKAs and DOACs do not share the same 
mechanism of action. This fact distinguishes both kinds of 
anticoagulant, meaning that VKAs could be more suitable 
for one individual but DOACs for another. Moreover, 
VKAs and dabigatran have different metabolic pathways 
and as different polymorphisms affect metabolism of both 
kind of drugs, knowing the specific genotype of each 
individual before starting anticoagulant treatment could 
help avoid adverse events. For instance, a sub-study of 
the ENGAGE-AF-TIMI 48 trial demonstrated that patients 
with the CYP2C9 and VKORC1 variants can benefit 
more from edoxaban compared to warfarin [113, 114]. 
Therefore, a personalized medicine for oral anticoagulants 
use is possible based on the fact that DOACs and VKAs 
involve different metabolic pathways and GWA studies 
confirm that different genetic risk factors are associated 
with the response of both types of drug.
FUTURE
It is expected that around year 2020 the results of 
large randomized clinical trials on the incorporation of 
pharmacogenetics algorithms to guide VKAs dosage will 
become available. Furthermore, by this time, it is likely 
that genotyping will be quickly and more cost-effective. 
It is expected that the use of pharmacogenetics algorithms 
for vitamin K inhibitors will reduce adverse reactions to 
these drugs [3].
Pharmacogenetic studies with DOACs would help 
to choose the most appropriate anticoagulant treatment for 
each patient. Thus, pharmacogenetics studies have to be 
translational, to include genotyping in clinical practice and 
achieve a more personalized medicine, as happens with 
other kind of treatments, such as in cancer [115, 116].
The applicability of pharmacogenetics in clinical 
practice has been mainly demonstrated with cancer 
treatments. Nowadays, there are cancer drugs which are 
dosed following pharmacogenetic tests. The genotyping 
of thiopurine S-methyltransferase (TPMT) in acute 
lymphoblastic leukemia (ALL) patients before treatment 
with 6-mercaptopurine is useful to select the correct 
dose based on genetics before the first drug intake. After 
changing the label for 6-mercaptopurine in 2004, some 
hospitals routinely started to order TPMT genotyping 
before initiation of the treatment [117].
In advanced colorectal cancer, irinotecan is the 
most widely-used drug. However, polymorphisms in 
diphosphate-glucuronosyltransferase 1A1 (UGT1A1) have 
been found to be associated with the risk of developing 
hematological and/or digestive toxicities. Thus, dose 
reduction was recommended in patients with the genotype 
*28/*28. In United States, the FDA recommended genotyped 
the UGT1A1 *28 variant before irinotecan prescription. 
In Europe, a Dutch workgroup and the French National 
Thesaurus of Digestive Oncology recommended dose 
reduction in *28/*28 patients [118]. A genotyping test has 
been generated to facilitate the detection of this genetic 
variation UGT1A1 (Mayo Medical Laboratory) [117, 119].
Other genes associated with adverse drug events 
with potential benefits for use in clinical practice could 
be: CYP2D6 and tamoxifen for breast cancer, DPYD and 
fluoropyrimidine antimetabolite 5-fluorouracil (5-FU) for 
colon cancer, SLCO1B1 and Simvastatin for the reduction 
of cholesterol levels, HLA-A*33:03 and ticlopidine for 
secondary prevention of atherothrombosis [117, 120].
Current medicine could incorporate 
pharmacogenetics to offer patients an effective 
personalized medicine by adjusting treatment and dosage 
in those cases with a proven genetic association based on 
GWAs analysis and subsequent approval by the FDA or 
the European authorities. This way, adverse events related 
with lack or excess of drug effect could be decreased.
LIMITATIONS
This review has some limitations. First, the idea 
was to revise and analyze all the GWAS published for the 
different OAs. However, for some of them (fluindione, 
edoxaban, rivaroxaban and apixaban), there are no studies 
that have performed GWAS analysis with these drugs. In 
these cases, other genetic studies based on gene candidates 
were reviewed. Nevertheless, these kind of studies are 
biased, as they are based on a previous hypothesis and do 
not replicate the results in independent populations. Thus, 
their reliability is limited. It would be necessary to perform 
a GWAs approach to really identify genes involved in the 
secondary response to these drugs.
Second, for many polymorphisms found associated 
with the effect of different OAs is assumed that the 
effector gene is the closest to the mutations. However, 
this is not always true and in vitro or in silico functional 
analysis have to be performed to demonstrate the effector 
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